SCHAUMBURG, Ill.--(BUSINESS WIRE)—January 20, 2009—APP Pharmaceuticals, Inc., a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has launched Rocuronium Bromide Injection, the generic equivalent of Organon’s Zemuron®.
“In addition to safety measures such as barcoding and latex-free stoppers, APP has incorporated a peel off syringe label on all of its rocuronium vials,” said Thomas H. Silberg, president and chief executive officer of APP Pharmaceuticals. "Adding this feature to the vials enables healthcare facilities to comply with National Patient Safety Goal 3D, which requires labeling on all medications, syringes for perioperative and other procedural settings.”
APP’s rocuronium is AP-rated and preservative-free, and is marketed in two dosage forms, 50 mg/5mL and 100 mg/10 mL. One of the most widely used muscle relaxants in the United States, Canada and many European countries, according to IMS data, 20071 sales of rocuronium in the United States were approximately $127 million or 10 million units.
Used predominately in hospitals and clinics in general anesthesia, rocuronium is an intravenous neuromuscular blocking agent (NMBA) that is administered during surgery to facilitate safe and rapid endotracheal intubation (insertion of a tube in the windpipe to facilitate artificial ventilation) and provide total skeletal muscle relaxation. Rocuronium is a nondepolarizing neuromuscular blocking agent that unlike other NMBA’s provides immediate muscular relaxation.
1 2005-2007 Annualized IMS Data
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company’s Web site at www.APPpharma.com.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions for fluid substitution, blood volume expansion, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy “Caring for life” and a comprehensive product portfolio, the company aims at improving the quality of life of patients all over the world. On September 30, 2008, the company had 20,504 employees. In 2007, Fresenius Kabi achieved sales of EUR 2,030 million and an operating profit of EUR 332 million. For more information visit the company’s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE. Fresenius SE is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
About Fresenius SE
Fresenius SE is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approximately EUR 11.4 billion. On September 30, 2008, the Fresenius Group had 121,288 employees worldwide. For more information visit the company’s Web site at www.fresenius.com.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of rocuronium bromide injection. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. prospectus dated August 20, 2008, and other documents the company has filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.
Zemuron® is a registered trademark of Organon USA Inc.
Debra Lynn Ross
Director, Corporate Communications
APP Pharmaceuticals, Inc.
Investor and Media Inquiries
Hill & Knowlton
SOURCE: APP Pharmaceuticals, Inc.